The Mazda Pharma Guide 7th October to 13th October | Page 60

?
?
PHARMACEUTICAL NEWS
GLENMARK
GENERICS GETS US

subsidiary of Glenmark Pharmaceuticals

this transaction were £177 million in the first

Limited (Glenmark) and aims to be a global

half of 2013.

integrated Generic and API leader.

David Redfern, chief strategy officer,

FDA NOD FOR

ASPEN TO ACQUIRE

HYDROCORTISONE

GLAXOSMITHKLINE'S

BUTYRATE CREAM

THROMBOSIS

is on delivering an unprecedented late-stage

BRANDS AND

pipeline and preparing for the launch of

Mumbai : Glenmark Generics Inc., the US
subsidiary of Glenmark Generics Limited, has

GSK, said: “Arixtra and Fraxiparine are
established products that have consistently
delivered strong revenues. However, our focus

approved medicines. Aspen is a long-term

received the United States Food and Drug

RELATED

partner of GSK and will be able to dedicate

Administration (FDA) approval for

MANUFACTURING

the resources that these products deserve to

abbreviated new drug approval (ANDA),
Hydrocortisone Butyrate Cream USP, 0.1 per

SITE FOR £70

cent. Hydrocortisone Butyrate Cream is a

MILLION

take them forward. Importantly, we are
pleased to be able to preserve the vast
majority of jobs through this agreement.”

generic version of Locoid Lipocream.

London, UK : GlaxoSmithKline has reached

The Hydrocortisone Butyrate Cream is

agreement to sell its thrombosis brands,

Aspen, a leading generics manufacturer in the

indicated for relief of inflammatory and

Arixtra and Fraxiparine, and the Notre-Dame

southern hemisphere and Africa's largest

pruritic manifestations of corticosteroid-

de Bondeville (NDB) manufacturing site to

pharmaceutical manufacturer.

responsive dermatoses in adults and the

The Aspen Group (Aspen), the South African

treatment of mild to moderate atopic

pharmaceuticals company, for £0.7 billion in

dermatitis in patients three months to 18 years

cash, of which £0.1 billion relates to

RELOCATE US R&D

of age.

inventory. The agreement is a further example

ACTIVITIES TO

In April 2011 Glenmark had entered

of GSK's commitment to increase focus on

into a royalty-bearing license agreement with

products with the most growth potential and

Triax Pharmaceuticals, Astellas Pharma

the delivery of its late-stage pipeline.

Europe BV and Astellas Pharma International

The net cash proceeds from the

BV to settle a patent infringement suit against

transaction after tax and transaction costs are

the commercialization of generic version of

expected to be approximately £0.6 billion.

Locoid Lipocream and agreed to launch in

The proceeds will be used for general

near the end of CY 2013. Glenmark is entitled

corporate purposes. The net profit on disposal

to 180 days of exclusivity with respect to its

will be excluded from core operating profit

Hydrocortisone Butyrate Cream, as it is the

and core EPS in 2013.

first generic company to file an ANDA for the
product.

Aspen will acquire global rights to the
Arixtra and Fraxiparine brands (excluding

According to IMS Health sales data for China, India and Pakistan) and certain
the 12 month period ending June 2013,
dedicated commercial employees, along with
Hydrocortisone Butyrate Cream garnered
annual sales of approximately US$ 34 million.
Glenmark's current portfolio consists

the related NDB manufacturing site and the
majority of employees at NDB in France. In
Indonesia, GSK will cont ??VRF?F?7G&?'WFR?@???b?&?GV7G2WF??&??VBf?"F?7G&?'WF??????&?WBF?R'&?G2V?FW"?6V?6Rg&??7V??F?RU2?&?WG?6R?BS2?Dw2V?F??p??7V&?V7BF?&VwV?F?'?&?f?2??B?2W?V7FV@??&?f?v?F?F?RU2dD???FF?F???F???F?BF?R???&?G??b6???W&6???W&F???0??F?W6R??FW&??f???w2?tt?6??F??VW2F???v???G&?6fW"F?7V?'?F?RV?B?bF?R?V ???FV?F?g??BW???&RW?FW&??FWfV???V?@??v?F?F?R&V???FW"????rv?F?F?R?D"6?FR???'F?W'6??2F?7W?V?V?B?B66V?W&FRF?P??F?f????r??F?Rf?'7B??b?b#B?F?F?6?W0??w&?wF??bF?RW??7F??r?V??R?B?'Ff?????v?V??&?vV?W&?72??FVB?tt??2??c???bF?W6R&?GV7G2??F?RFW'&?F?&?W27V&?V7BF???u4??&VG??2???bR???F??r???4T???2D????544?U4UEE0?&?2?g&?6R??6V??2???VBF?&V??6FP??G2U2&W6V&6??BFWfV???V?B?"dB???W&F???2g&????f?&BF?6?'&?FvR???766?W6WGG2v??6??2?VF??r?V"f? ?&??FV6?????w?&W6V&6??F??26?FRv???&R?W??f?"????fF?????F&vWFVBF?W&?W27&?70??6V?w27V6??G?&V22vV??26V?FW"?`?W?6V??V?6Rf?"WF?FW2??F??2??fRv????6?'&??r?6V?6??6W ?F?6WfW&??W?'F?W'2&6VB??F?P?6?'&?FvR&V???6?VF??r&???V?B??7?F??6V?G&W2??VF?6?66????2?&??FV6?6????W0??BV??fW'6?F?W2?F?W&V'?gW'F?W"&???F??p??Bf6??FF??r'F?W'6??2?B?V????fF?????( ?&V??6F???F?6?'&?FvR&W&W6V?G2????"?Vf?'v&Bf?"?6V?w2"d@?7F?f?F?W2?( ?6?B6?VFR&W'G&?B?W?V7WF?fP?f?6R&W6?FV?B?B6??Vb66?V?F?f?2?ff?6W"???6V??( ?gFW"F?R7V?6?F????b7??F?????6????BF?R7WGF??rVFvR?bF????&W6V&6???F??2??fR?2??F?W"?6?F?fR??W7F??R??F?P?6??6??FF????b?6V?w2v??&??VFW'6????D?R??D?$?uT?DR?r?7F?&W"?2?7F?&W"#0??